Smart Drug Development & Design from Candidate to Phase I
March 8, 2018
Since the sequencing of the human genome nearly two decades ago, scientists have made numerous breakthroughs in understanding disease pathophysiology and developing molecules for “undruggable” targets. However, the pharmaceutical industry continues to experience decreasing productivity and high levels of attrition. One reason is that novel small molecule drugs have inflated physicochemical properties, which lead to low bioavailability and poor safety and efficacy profiles. Addressing these issues early and comprehensively can result in fewer problems in later development phases such as escalating timelines, costs, and regulatory issues. Leveraging the skills and experience of experts and integrating competencies can optimize the development pathway and enable drug candidates to reach their true potential.
This event will focus on key considerations for transitioning a molecule from discovery to phase 1 readiness including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of patient focus design principles.